نتایج جستجو برای: capecitabine

تعداد نتایج: 4646  

Journal: :The oncologist 2006
Karen Gelmon Arlene Chan Nadia Harbeck

Capecitabine is an important drug in the therapeutic armamentarium for metastatic breast cancer. A comprehensive worldwide clinical trial program involving >10,000 patients with locally advanced and metastatic breast cancer has provided evidence for the current treatment strategies. On the basis of data demonstrating consistent activity across several trials in patients with heavily pretreated ...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2012
C Twelves W Scheithauer J McKendrick J-F Seitz G Van Hazel A Wong E Díaz-Rubio F Gilberg J Cassidy

BACKGROUND This multicenter randomized trial compared oral capecitabine with bolus i.v. 5-fluorouracil (5-FU)/folinic acid (FA) as adjuvant therapy for stage III colon cancer. PATIENTS AND METHODS Patients were assigned to 24 weeks of capecitabine 1250 mg/m(2) twice daily on days 1-14 every 3 weeks or 5-FU/FA (Mayo Clinic regimen). The primary end point was disease-free survival (DFS). RESU...

Journal: :Genetics and molecular research : GMR 2015
J J Zhu J J Shan L B Sun W S Qiu

The purpose of this study was to explore the radiotherapy sensitization effects and the mechanism of capecitabine (Xeloda) against the non-small-cell lung cancer cell line, A549. γ-[(60)Co] radiation was used as the intervention method. Proliferative inhibition of capecitabine on A549 cells was determined by the CCK-8 method. The effects of capecitabine on the apoptosis rate and cell cycle dist...

2011
Katherine H. Rak Tkaczuk

Breast Cancer is the most prevalent cancer in the world with 4.4 million survivors up to 5 years following the diagnosis.1 In the US alone approximately forty thousand women die annually of metastatic breast cancer (MBC). Despite many effective systemic treatment options approximately 50% of women with MBC succumb to the disease within 24 months of the diagnosis.2 Ixabepilone is a novel, first ...

2005
B. T. Hennessy A. M. Gauthier L. B. Michaud G. Hortobagyi V. Valero

Background: Capecitabine is active against anthracyclineand taxane-pretreated metastatic breast cancer. Post-marketing use of capecitabine at the FDA-approved dose (2500 mg/m/day) leads to unacceptable toxicity in many patients. Dose reductions anecdotally improve tolerability without compromising efficacy. This retrospective analysis was designed to verify these anecdotal reports. Patients and...

Journal: :JOP : Journal of the pancreas 2007
Muhammad Wasif Saif Soonmo Peter Kang Leslie Ledbetter Adam Steg Robert Diasio Martin Johnson

CONTEXT Capecitabine has shown efficacy in treatment of metastatic pancreatic cancer. Several researchers have identified thymidine phosphorylase, dihydropyrimidine dehydrogenase, or their ratio as indicators of response to capecitabine in various cancers. CASE REPORT We report two patients with metastatic pancreatic carcinoma who had long-term survivals on capecitabine after gemcitabine fail...

2013
Somnath Mukherjee Christopher N Hurt John Bridgewater Stephen Falk Sebastian Cummins Harpreet Wasan Tom Crosby Catherine Jephcott Rajarshi Roy Ganesh Radhakrishna Alec McDonald Ruby Ray George Joseph John Staffurth Ross A Abrams Gareth Griffiths Tim Maughan

BACKGROUND In the UK, chemotherapy is the standard treatment for inoperable, locally advanced, non-metastatic pancreatic cancer. Chemoradiotherapy is also an acceptable treatment option, for which gemcitabine, fluorouracil, or capecitabine can be used as concurrent chemotherapy agents. We aimed to assess the activity, safety, and feasibility of both gemcitabine-based and capecitabine-based chem...

2001
Eric Van Cutsem Chris Twelves Jim Cassidy David Allman Emilio Bajetta Michael Boyer Roland Bugat Mike Findlay Stefan Frings Michaela Jahn Joe McKendrick Bruno Osterwalder Gumersindo Perez-Manga Riccardo Rosso Philippe Rougier Wolff H. Schmiegel Jean-Francois Seitz Paul Thompson Jose Maria Vieitez

Purpose: To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at the tumor site, with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer. Patien...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Dan Laheru Gary Croghan Ronald Bukowski Michelle Rudek Wells Messersmith Charles Erlichman Robert Pelley Antonio Jimeno Ross Donehower Joseph Boni Richat Abbas Patricia Martins Charles Zacharchuk Manuel Hidalgo

PURPOSE To determine the maximum tolerated dose (MTD), characterize the principal toxicities, and assess the pharmacokinetics of EKB-569, an oral selective irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with capecitabine in patients with advanced colorectal cancer. EXPERIMENTAL DESIGN Patients were treated with EKB-569 daily for 21 days and cape...

Journal: :Molecules 2018
Piotr Cmoch Piotr Krzeczyński Andrzej Leś

The molecular structure of capecitabine (a widely applied prodrug of 5-fluorouracil) was studied by multinuclear NMR measurements and DFT quantum mechanical calculations. One or two tautomeric forms in a solution were detected depending on the solvent used. In the organic solvents, a mixture of two forms of capecitabine was observed: carbamate and imine tautomers. In the aqueous solution, only ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید